Table 2.

Baseline and changes in outcome measurements after 8 weeks (N = 52).

Variable	Group	Mean (SD) Before	Mean (SD) After	Mean difference (after-before)	95% Confidence Interval of the Difference	P-value within groups	P-value between groups
BMI(kg/m2)	LS	46.23 ± 4.57	45.01 ± 4.44	−1.21	−1.79)-(-0.63))	0.00	0.02
	LP	46.42 ± 3.67	46.32 ± 3.91	−0.10	−1.95)-(1.73))	0.90
AST	LS	35.81 ± 16.57	30.22 ± 15.94	−5.59	−6.90)-(-4.19))	0.00	0.00
	LP	41.24 ± 12.29	40.04 ± 13.39	−1.20	−2.70)-(0.30))	0.12
ALT	LS	39.64 ± 17.98	34.59 ± 17.44	−5.05	−6.72)-(-3.38))	0.00	0.01
	LP	43.84 ± 11.99	47.68 ± 10.88	3.84	−1.05)-(8.73))	0.11
AST/ALT ratio	LS	0.96 ± 0.20	0.85 ± 0.29	−0.10	−0.19)-(-0.03))	0.04	0.04
	LP	0.93 ± 0.33	0.92 ± 0.41	−0.07	−0.57)-(0.42))	0.76
NAFLD Score	LS	−0.72 ± 1.63	−0.67 ± 1.15	0.05	−0.37)-(0.49))	0.78	0.75
	LP	−0.34 ± 1.63	−0.34 ± 1.64	−0.009	−0.09)-(0.00))	0.17
Fib4 Score	LS	0.71 ± 0.32	0.69 ± 0.30	0.20-	−0.07)-(0.03))	0.42	0.90
	LP	0.66 ± 0.32	0.63 ± 0.33	−0.20	−0.46)-(0.00))	0.42

LS, lifestyle modification + silymarin; LP, lifestyle modification + placebo.